Acute Heart Failure – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Acute Heart Failure – Drugs In Development, 2024 report and make more profitable business decisions.
Acute heart failure (AHF) is a critical medical condition characterized by a sudden onset or rapid worsening of symptoms related to the heart’s inability to pump blood effectively. This leads to insufficient oxygen delivery to tissues and organs. AHF can manifest as either new-onset heart failure or exacerbation of chronic heart failure. Common symptoms include shortness of breath, fatigue, and fluid retention, often resulting in pulmonary congestion and peripheral edema. Various factors such as coronary artery disease, hypertension, or infections can precipitate AHF. Prompt diagnosis, often through clinical evaluation and imaging, guides immediate interventions, including medications and, in severe cases, mechanical support or surgical interventions to optimize cardiac function and improve outcomes.
The Acute Heart Failure drugs in development market research report provide comprehensive information on the therapeutics under development for Acute Heart Failure, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Acute Heart Failure and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Acute Heart Failure | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 19 molecules, with 19 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Acute Heart Failure therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Acute Heart Failure pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Acute Heart Failure treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
4TEEN4 Pharmaceuticals GmbHAdrenomed AG
AnaCardio AB
Boehringer Ingelheim International GmbH
Bristol-Myers Squibb Co
Corteria Pharmaceuticals SAS
Guangzhou Diqi Pharmaceutical Technology Co Ltd
Inserm Transfert SA
Madeleine Pharmaceuticals Inc
Rnatives Inc
Rockwell Medical Inc
Shandong Danhong Pharmaceutical Co Ltd
Shijiazhuang Wotai Biotechnology Co Ltd
Shin Poong Pharm Co Ltd
Toa Eiyo Ltd
ViCardia Therapeutics Inc
Windtree Therapeutics Inc
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Acute Heart Failure reports